Abstract 1639P
Background
Outcomes and risk factors associated with COVID-19 worsening among cancer patients have previously been reported. However, the actual impact of SARs-Co-V2 infection on the cancer treatment strategy remains unknown. Here, we report the Gustave Roussy (GR) experience, one year after the onset of the pandemic focusing on the impact of COVID-19 in patients with ongoing management of oncohematological disease.
Methods
All patients positively tested for SARS-CoV-2 and managed at GR between Mar 14th 2020 and Feb 15th 2021 (data cut-off) have been included. Patients underlying oncohematological disease and COVID19 characteristics have been collected. Cancer and COVID-19 management and outcomes have been assessed. Primary endpoint was the overall impact of COVID-19 on oncological and hematological treatment strategy assessed at 1, 3, 6 and 12 months.
Results
At the time of the analysis, 423 patients (median age: 62 years) were found positive for SARS-CoV-2 and managed at GR with a median follow up of 5.6 months (0-13 months). Among them, 284 (67%) were admitted due to COVID-19. Clinical deterioration occurred in 87 patients (21%), 43 patients (10%) were transferred in intensive care unit and 123 (29%) patients died, among which 47 (11%) died from COVID-19. Overall, 329 (78%) patients were on active treatment for underlying oncohematological disease at time of COVID diagnosis. Impact of COVID-19 on cancer treatment strategy in those patients is presented in the Table. The majority (N=268, 81%) had no change in oncological strategy. For those who experienced a delay, median delay in treatment was 21 days (N=99, [1-77]), 30 days (N=15, [15-56]), 7 days (N=8,[3-35]) for systemic treatment, surgery and radiotherapy respectively. Table: 1639P
Impact of COVID-19 on cancer treatment strategy in patients with active oncohaematological treatment at time of COVID-19 diagnosis
| N=329 | |
| Death from COVID-19 | 36 (11%) |
| No change in strategy | 268 |
| Without delay | 136 (41%) |
| With Delay | 132 (40%) |
| Change in strategy | 22 |
| End of treatment – Surveillance | 8 (2%) |
| End of treatment – Palliative care | 7 (2%) |
| Change of treatment modality | 6 (2%) |
| Change of systemic therapy | 1 (<1%) |
| NA | 3 (<1%) |
Conclusions
COVID-19 outbreak is associated with a significant mortality in patients with cancer. However, for patients who did not die from COVID-19, we provide the first report supporting that ongoing treatment was maintained or could be resumed in the majority of cases in a timely manner.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.